Seeking value primarily in the non-US developed markets

The international value portfolio is constructed from an equity universe composed of companies with market capitalizations typically greater than $1 billion located throughout the non-US developed and emerging market countries. Through rigorous, bottom-up company analysis, we seek to identify undervalued stocks with upside potential. The investment process comprises three stages: quantitative screening and initial analysis, fundamental research and portfolio construction.

Benchmark
MSCI EAFE
Inception
June 11, 2001
Download Profile Sheet Download Flash Report Download Quarterly Review Risk Disclosures
Contact Us

Strategy overview

The portfolio managers discuss our International Value strategy.

Portfolio managers

Fundamental Portfolio Manager
Fundamental Portfolio Manager
President
Head of Fundamental Research
Fundamental Portfolio Manager
Chief Executive Officer
Fundamental Portfolio Manager
Fundamental Portfolio Manager
Fundamental Portfolio Manager
Fundamental Portfolio Manager
Fundamental Portfolio Manager

Performance

Table Header QTD YTD 1 year3 years5 years10 years Since inception
Strategy (gross) 9.4%9.4%38.1%23.4%15.5%12.6%9.3%
Strategy (net) 9.4%9.4%37.6%23.0%15.1%12.2%8.9%
MSCI EAFE 10.1%10.1%35.3%19.4%11.3%10.8%6.9%
Table Header QTD YTD 1 year3 years5 years10 years Since inception
Strategy (gross) 9.4%9.4%38.1%23.4%15.5%12.6%9.3%
Strategy (net) 9.4%9.4%37.6%23.0%15.1%12.2%8.9%
MSCI EAFE 10.1%10.1%35.3%19.4%11.3%10.8%6.9%
Table Header QTD YTD 1 year3 years5 years10 years Since inception
Strategy (gross) 8.4%40.2%40.2%24.2%14.4%10.5%9.0%
Strategy (net) 8.3%39.7%39.7%23.7%14.0%10.1%8.5%
MSCI EAFE 4.9%31.9%31.9%17.8%9.5%8.7%6.5%
Table Header QTD YTD 1 year3 years5 years10 years Since inception
Strategy (gross) 8.4%40.2%40.2%24.2%14.4%10.5%9.0%
Strategy (net) 8.3%39.7%39.7%23.7%14.0%10.1%8.5%
MSCI EAFE 4.9%31.9%31.9%17.8%9.5%8.7%6.5%
Fund 202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002
Strategy (gross) 40.2%5.9%29.0%-7.2%10.5%6.1%22.5%-18.0%28.6%1.1%-1.9%-4.6%27.6%24.6%-10.2%13.9%37.7%-43.0%9.8%27.5%9.0%29.5%48.4%-8.9%
Strategy (net) 39.7%5.5%28.5%-7.6%10.1%5.6%22.0%-18.4%28.0%0.7%-2.3%-5.0%27.1%24.1%-10.5%13.4%37.1%-43.2%9.4%27.0%8.5%29.0%47.8%-9.2%
MSCI EAFE 31.9%4.3%18.9%-14.0%11.8%8.3%22.7%-13.4%25.6%1.5%-0.4%-4.5%23.3%17.9%-11.7%8.2%32.5%-43.1%11.6%26.9%14.0%20.7%39.2%-15.7%
Table Header
Strategy (gross)
Strategy (net)
MSCI EAFE
202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002
40.2%5.9%29.0%-7.2%10.5%6.1%22.5%-18.0%28.6%1.1%-1.9%-4.6%27.6%24.6%-10.2%13.9%37.7%-43.0%9.8%27.5%9.0%29.5%48.4%-8.9%
39.7%5.5%28.5%-7.6%10.1%5.6%22.0%-18.4%28.0%0.7%-2.3%-5.0%27.1%24.1%-10.5%13.4%37.1%-43.2%9.4%27.0%8.5%29.0%47.8%-9.2%
31.9%4.3%18.9%-14.0%11.8%8.3%22.7%-13.4%25.6%1.5%-0.4%-4.5%23.3%17.9%-11.7%8.2%32.5%-43.1%11.6%26.9%14.0%20.7%39.2%-15.7%

Portfolio (as of February 28, 2026)

Benchmark: MSCI EAFE
Asset Allocation
Table Header Strategy
Stocks 97.2%
Cash 2.8%
Strategy Characteristics
Table Header Strategy Benchmark
No. of holdings 67 692
Weighted avg. market cap (US $MM) $96,119 $107,274
FY2 price/earnings 13.0 15.5
Price/book value 1.9 2.3
Dividend yield (%) 2.3 2.6
TOP 10 HOLDINGS
Security Country Percent
Kering SA France 4.9%
Renesas Electronics Corp. Japan 4.0%
AstraZeneca PLC United Kingdom 3.8%
Alstom SA France 3.7%
SMC Corporation Japan 2.7%
Reckitt Benckiser Group Plc United Kingdom 2.7%
Roche Holding AG Switzerland 2.7%
Barclays PLC United Kingdom 2.6%
BNP Paribas SA France 2.5%
SAP SE Germany 2.4%

A “weighted average” measures a characteristic by the market capitalization of each stock. Price/book ratio is the weighted average of the price/book ratios of all the stocks in a portfolio. The P/B ratio of a company is calculated by dividing the market price of its stock by the company’s per-share book value. The price/earnings ratio is the weighted average of the price/earnings ratios of the stocks in a portfolio. The FY2 P/E ratio is a forward P/E ratio using a next-twenty-four months EPS estimate in the denominator.

Holdings are subject to change.

SECTOR WEIGHTS
Sector Strategy Benchmark
Industrials 18.7% 20.1%
Financials 18.4% 24.6%
Information Technology 13.5% 8.6%
Health Care 12.9% 11.1%
Consumer Discretionary 9.8% 9.0%
Consumer Staples 8.8% 7.4%
Communication Services 4.7% 4.1%
Materials 4.1% 6.0%
Utilities 3.4% 3.9%
Energy 1.7% 3.4%
Real Estate 1.2% 1.9%
TOP 10 COUNTRIES
Country Strategy Benchmark
United Kingdom 27.8% 14.9%
France 19.3% 10.3%
Japan 12.1% 23.3%
Germany 10.3% 9.2%
Netherlands 5.7% 5.3%
United States 3.3% 0.0%
South Korea 3.0% 0.0%
Switzerland 2.7% 9.5%
Italy 2.5% 3.2%
Sweden 2.2% 3.7%
Regional Allocation
  • Euro 39.7%
  • Europe - Other 34.3%
  • Pacific 13.0%
  • North America 5.2%
  • Emerging Asia 4.5%
  • Emerging Europe, Middle East, Africa 0.4%

Commentary (As of February 28, 2026)

Highlights

  • In February, developed international and emerging markets advanced while US equities declined, with value stocks outperforming growth across all three segments.
  • In the absence of a prolonged geopolitical conflict in the Middle East, sustained earnings growth and abundant global liquidity could lift global equity market levels into 2026. While inflation progress remains uneven, G-7 central banks face mounting political and economic pressure to prioritize growth, suggesting an accommodative bias in monetary policy.
  • As leadership broadens across global equity markets, we see an expanding opportunity set for disciplined, valuation-based active management.

Portfolio Attribution

The Portfolio modestly underperformed the Index during the month, due primarily to currency allocation (a byproduct of our bottom-up stock selection process). Portfolio holdings in the pharmaceuticals & biotechnology, banks, and materials industry groups detracted from relative performance compared to the Index. Holdings in the semiconductors & semi equipment, technology hardware & equipment, and health care equipment & services industry groups offset some of the underperformance compared to the Index. The largest detractor was global healthcare company, Novo Nordisk A/S (Denmark). Additional notable detractors included information technology services and consulting company, Capgemini SE (France), and specialty chemicals company, Syensqo NV (Belgium). The top contributor to return was electronic equipment manufacturer, Samsung Electronics Co., Ltd. (South Korea). Other notable contributors included pneumatic controls manufacturer, SMC Corporation (Japan), and semiconductor company, Renesas Electronics Corp. (Japan).

Investment Outlook

In the absence of a prolonged geopolitical conflict in the Middle East, sustained earnings growth and abundant global liquidity could lift global equity market levels into 2026. While inflation progress remains uneven, G-7 central banks face mounting political and economic pressure to prioritize growth, suggesting an accommodative bias in monetary policy. In the United States, assuming no material escalation in tariffs and inflation, favorable tax and regulatory conditions should underpin continued economic expansion. We expect AI-driven capital expenditures to broaden beyond graphics processing units (GPUs) into power infrastructure, data center development, cooling, and networking. Accessible credit and a less restrictive regulatory backdrop appear also likely to drive a surge in M&A activity across major developed markets, supporting both public and private asset valuations. Europe and Japan could attract increased global capital flows if deregulation efforts persist and Europe advances toward deeper single-market integration and institutional coordination. Political polarization and potential voter backlash remain risks to the pace and durability of reform in both the US and Europe, especially if inflation re-accelerates or AI-related employment concerns intensify.

With conflict-induced spikes in market volatility, stock selection remains paramount. We expect some of the portfolio’s most attractive opportunities to come from companies undergoing operational restructuring, where capable management teams can re-accelerate cash flow growth—often in currently unpopular areas such as industrials and consumer staples. In health care, we are focused on businesses with durable pricing power, established franchises, and underappreciated pipelines, viewing periodic setbacks as potential entry points. We also see improving prospects among technology laggards, particularly where we believe cyclical challenges are being misread as structural. Our research seeks to distinguish permanent impairment from temporary disruption, especially in IT Services, enterprise software, and analog semiconductors, while carefully assessing the implications of rising Chinese competition.

Periods of market volatility may lead to short-term price dislocations. As active managers, we view such volatility as both a risk to be managed and a potential opportunity to initiate or add to high-conviction positions at attractive valuations, provided our fundamental thesis remains intact.

As leadership broadens across global equity markets, we see an expanding opportunity set for disciplined, valuation-based active management. By focusing on cash flow trajectory, balance sheet strength, and management execution, we seek to identify mispriced securities where we believe long-term fundamentals are not fully reflected in current valuations.

The market commentary expresses the portfolio managers’ views as of the date of this report and should not be relied on as research or investment advice regarding any stock. These views and the portfolio holdings and characteristics are subject to change. There is no guarantee that any forecasts made will come to pass. The securities identified and described above do not represent all of the securities purchased, sold or recommended for client accounts. The reader should not assume that an investment in the securities identified was or will be profitable. Past performance does not guarantee future results. For a description of our performance attribution methodology, or to obtain a list showing every holding's contribution to the overall account's performance during the quarter, please contact our product manager, Kevin Moutes, at 310-231-6116 or [email protected].